Ascendis Pharma (ASND) PT Raised to $325 at Stifel Following Q4 Results

Stifel analyst Alex Thompson raised the price target on Ascendis Pharma (NASDAQ: ASND) to $325.00 (from $256.00) while maintaining a Buy rating.

The analyst commented, "We are reiterating our Buy Rating on ASND following their 4Q25 release. Following the early-January pre-report and 52wk COACH data, updates are in-line. The Yorvipath launch remains the main driver for shares in 2026, in our view. Recent KOL feedback (LINK) along with management commentary around steady growth through the year, are consistent with our view that the addressable market is much larger than the theoretical "not well managed" population, and we think 2026 consensus remains too conservative and implies slowing of net patient adds. Beyond Yorvipath, the CNP PDUFA is on track for 2/28-- ASND is prepared to launch while the company also plans to move into late-stage development for the CNP/hGH combo following an EoP2 meeting. We have updated our model for the quarter taking the 2026 €500MM in operating cash flow guide with stable opex y/y flowing through the out-years--our TP goes to $325 from $256."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)